NCT07632664 Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients
| NCT ID | NCT07632664 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Lung Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2024-08-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter prospective clinical study focuses on elderly patients with lung cancer. The investigators will build a standardized clinical registry database, develop perioperative risk stratification and surgical early-warning models, optimize individualized surgical regimens, construct multidisciplinary perioperative comprehensive therapy, integrated Chinese-Western medicine full-cycle management and personalized postoperative rehabilitation systems, so as to form a whole-process optimized treatment model for elderly lung cancer.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥65 years old 2. Pathologically confirmed non-small cell lung cancer with clinical stage eligible for curative surgical resection 3. Complete preoperative geriatric comprehensive assessment data available 4. Capable of finishing planned surgery and long-term follow-up 5. Voluntarily sign informed consent form Exclusion Criteria: 1. History of other malignant tumors within recent 5 years 2. Severe organic dysfunction of heart, liver, renal or respiratory system that cannot tolerate thoracic surgery 3. Preoperative confirmed distant metastasis preventing radical resection 4. Uncontrolled active severe infection or obvious coagulation disorders 5. Severe psychiatric disorder or cognitive dysfunction failing to cooperate with treatment and follow-up 6. Refuse random grouping and postoperative regular monitoring
Frequently Asked Questions
Who can join the NCT07632664 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Lung Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07632664 currently recruiting?
Yes, NCT07632664 is actively recruiting participants. Visit ClinicalTrials.gov or contact Peking University People's Hospital to inquire about joining.
Where is the NCT07632664 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07632664 clinical trial?
NCT07632664 is sponsored by Peking University People's Hospital. The trial plans to enroll 1,000 participants.